Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ genetics
Biomarkers, Tumor
Carcinoma, Squamous Cell
/ genetics
Case-Control Studies
Female
Gene Expression
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Mouth Neoplasms
/ genetics
Neoplasm Grading
Neoplasm Staging
Prognosis
Programmed Cell Death 1 Ligand 2 Protein
/ genetics
ROC Curve
OSCC
PD-L1
PD-L2
RT-qPCR
oral cancer
peripheral blood
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
25
08
2018
revised:
01
11
2018
accepted:
26
11
2018
pubmed:
20
1
2019
medline:
17
4
2020
entrez:
20
1
2019
Statut:
ppublish
Résumé
Despite the observed association of increased PD-L1 expression in peripheral blood of oral squamous cell carcinoma (OSCC) patients with histomorphologic parameters, the role of the PD1 ligands-PD-L1 and PD-L2-is insufficiently understood. Aim of the study was to investigate whether the alterations of PD-L1 and PD-L2 expression in blood are associated with survival and could serve as immune monitoring parameter. Moreover, it should be analyzed if PD-L2 is differentially expressed in tissue and blood samples of OSCC patients compared to healthy controls and if there is an association of PD-L2 expression with histomorphologic and prognostic tumor parameters. PD-L2 mRNA expression was analyzed in tumors and healthy oral mucosa specimens and in corresponding peripheral blood samples of 48 OSCC patients and 26 healthy controls using RT-qPCR. A cutoff point (COP) was determined and a chi-square test (χ PD-L2 expression in tissue samples was significantly (P < 0.001) higher in OSCC patients compared to healthy controls. A significant association of PD-L2 expression above the COP (positive) with malignancy was ascertained (P < 0.001). A significant (P = 0.01) association of previously reported PD-L1 expression rates in peripheral blood with survival could be shown. Peripheral blood PD-L1 expression might be a prognostic marker for OSCC patients and a possible parameter to monitor immune dysfunction in malign diseases. In the peripheral blood, PD-L1 might be more relevant for immune tolerance than PD-L2. Local PD-L2 expression in tissue samples might be useful as a diagnostic parameter for malignancy and could contribute to the immunosuppressive local microenvironment in OSCC.
Sections du résumé
BACKGROUND
Despite the observed association of increased PD-L1 expression in peripheral blood of oral squamous cell carcinoma (OSCC) patients with histomorphologic parameters, the role of the PD1 ligands-PD-L1 and PD-L2-is insufficiently understood. Aim of the study was to investigate whether the alterations of PD-L1 and PD-L2 expression in blood are associated with survival and could serve as immune monitoring parameter. Moreover, it should be analyzed if PD-L2 is differentially expressed in tissue and blood samples of OSCC patients compared to healthy controls and if there is an association of PD-L2 expression with histomorphologic and prognostic tumor parameters.
METHODS
PD-L2 mRNA expression was analyzed in tumors and healthy oral mucosa specimens and in corresponding peripheral blood samples of 48 OSCC patients and 26 healthy controls using RT-qPCR. A cutoff point (COP) was determined and a chi-square test (χ
RESULTS
PD-L2 expression in tissue samples was significantly (P < 0.001) higher in OSCC patients compared to healthy controls. A significant association of PD-L2 expression above the COP (positive) with malignancy was ascertained (P < 0.001). A significant (P = 0.01) association of previously reported PD-L1 expression rates in peripheral blood with survival could be shown.
CONCLUSION
Peripheral blood PD-L1 expression might be a prognostic marker for OSCC patients and a possible parameter to monitor immune dysfunction in malign diseases. In the peripheral blood, PD-L1 might be more relevant for immune tolerance than PD-L2. Local PD-L2 expression in tissue samples might be useful as a diagnostic parameter for malignancy and could contribute to the immunosuppressive local microenvironment in OSCC.
Identifiants
pubmed: 30659749
doi: 10.1002/cam4.1929
pmc: PMC6434218
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
PDCD1LG2 protein, human
0
Programmed Cell Death 1 Ligand 2 Protein
0
Banques de données
GENBANK
['NM_025239.3', 'NM_014143.3', 'NM_002046.5']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1124-1134Informations de copyright
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Hum Immunol. 2014 Apr;75(4):330-7
pubmed: 24486578
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Leukoc Biol. 2011 Apr;89(4):507-15
pubmed: 21097698
Cancer Treat Rev. 2018 Apr;65:54-64
pubmed: 29547766
Immunity. 2016 Aug 16;45(2):333-45
pubmed: 27533014
Front Immunol. 2016 Dec 12;7:550
pubmed: 28018338
Oncotarget. 2017 Oct 24;8(60):101994-102005
pubmed: 29254220
J Clin Oncol. 2016 Nov 10;34(32):3838-3845
pubmed: 27646946
Onco Targets Ther. 2017 Jun 13;10:2983-2992
pubmed: 28652780
Eur J Immunol. 2017 May;47(5):765-779
pubmed: 28393361
Mol Immunol. 2008 Aug;45(13):3567-72
pubmed: 18585785
Eur J Haematol. 2018 May;100(5):511-517
pubmed: 29377256
Oral Oncol. 2009 Apr-May;45(4-5):409-15
pubmed: 18715812
Cancer Res Treat. 2017 Jan;49(1):246-254
pubmed: 27456947
Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240
pubmed: 29355614
CA Cancer J Clin. 2005 Jul-Aug;55(4):242-58; quiz 261-2, 264
pubmed: 16020425
Dtsch Z Mund Kiefer Gesichtschir. 1985 Nov-Dec;9(6):461-8
pubmed: 3869490
Dtsch Z Mund Kiefer Gesichtschir. 1985 Nov-Dec;9(6):469-74
pubmed: 3869491
Immunity. 2016 May 17;44(5):955-72
pubmed: 27192563
Hum Pathol. 2018 Jan;71:91-99
pubmed: 29122656
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Cancer Med. 2019 Mar;8(3):1124-1134
pubmed: 30659749
Clin Cancer Res. 2017 Apr 15;23(8):1886-1890
pubmed: 27903674
Oncoimmunology. 2017 May 16;6(7):e1327494
pubmed: 28811964
Cancer. 1983 Oct 1;52(7):1165-72
pubmed: 6603897
Chin J Cancer. 2017 Jul 29;36(1):61
pubmed: 28754154
PLoS One. 2018 Feb 28;13(2):e0192704
pubmed: 29489833
Blood. 2010 Aug 26;116(8):1291-8
pubmed: 20472828
Iran J Allergy Asthma Immunol. 2016 Aug;15(4):296-302
pubmed: 27921410
Immunity. 2016 Aug 16;45(2):231-3
pubmed: 27533008
Curr Treat Options Oncol. 2017 Jul;18(7):40
pubmed: 28555375
Mol Immunol. 2011 Oct;49(1-2):1-3
pubmed: 22000002
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167
pubmed: 28619999
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Vaccines (Basel). 2016 Sep 02;4(3):
pubmed: 27598210
Biom J. 2005 Aug;47(4):458-72
pubmed: 16161804
Mol Immunol. 2011 Sep;48(15-16):2214-9
pubmed: 21752471
Oncotarget. 2017 Nov 8;8(68):112584-112597
pubmed: 29348848
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527